Craig Coleman
Professor/Pharmacy Practice

Are you Craig Coleman?

How to update your information.
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
2024
Craig Coleman, B Schaefer, M Carrier, C Ay, C Wallenhorst, M Rivera, A Ekbom, G Brobert, A T Cohen, K Abdelgawwad, C Martinez, G Psaroudakis, C Becattini, A A Khorana
Research Type: Journal Article

Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction model.
2024
William L Baker Jr., M J Christoph, B Koch, M Ouwens, G Frady, Craig Coleman, A Cohen, M Sharma, T E Moore
Research Type: Journal Article

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
2024
K Rhodes, Charles M White, Craig Coleman, H van Haalen, Youssef Bessada, K S Caroti, Adrian V Hernandez Diaz, P P Dobesh, William L Baker Jr.
Research Type: Journal Article

Agreement between 30-day and 90-day modified Rankin Scale score and utility-weighted modified Rankin Scale score in acute intracerebral hemorrhage: An analysis of ATACH-2 trial data.
2024
M J Christoph, A T Cohen, B Koch, William L Baker Jr., Craig Coleman, M Concha, B Lovelace
Research Type: Journal Article

Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
2024
G Brobert, C Becattini, K Vogtländer, M Linder, Craig Coleman, M Carrier, A A Khorana, A Ekbom, D H Giunta, Y Balabanova, A T Cohen, M Rivera, K Abdelgawwad, B Schaefer, G Psaroudakis
Research Type: Journal Article

Cost-Effectiveness of Olorofim in Invasive Aspergillosis Patients Lacking Suitable Alternative Treatment Options from a US Payer Perspective. ISPOR 2024, May 2024.
2024
Research Type: Poster/Presentation

Abstract WP231: The Incidence of Intracranial Hemorrhage in Patients Anticoagulated With Factor Xa Inhibitors (FXai): A Multi-Country Observational Study (AXIOM ICH).
2024
Research Type: Poster/Presentation

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.
2023
K S Caroti, B Schaefer, K Abdelgawwad, A T Cohen, M Carrier, C Brescia, A A Khorana, M Rivera, Craig Coleman, C Becattini, G Psaroudakis, A Ekbom, G Brobert
Research Type: Journal Article

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
2023
G Brobert, C Becattini, B Schaefer, Craig Coleman, K Abdelgawwad, M Carrier, A A Khorana, K S Caroti, G Psaroudakis, C Brescia, A Ekbom, M Rivera, A T Cohen
Research Type: Journal Article

Derivation and validation of a composite scoring system (SAVED(2)) for prediction of unfavorable modified Rankin scale score following intracerebral hemorrhage.
2023
A T Cohen, M J Christoph, B Koch, M Concha, Craig Coleman, B Lovelace
Research Type: Journal Article

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
2023
B Schaefer, S Fatoba, G Brobert, A Ekbom, M Rivera, G Psaroudakis, C Brescia, K Abdelgawwad, K S Caroti, C Becattini, Craig Coleman, M Carrier, A T Cohen, A A Khorana
Research Type: Journal Article

Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: A real-world analysis of Medicare beneficiaries.
2023
Craig Coleman, B Lovelace, J M Williams, M J Christoph, H Guo, S Li, M Hoover
Research Type: Journal Article

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
2023
Craig Coleman, H Chen, E Lesén, B Koch, J Ulloa, M Danese, P P Dobesh, T Dettling, G J Fermann, S Danese, M J Christoph, B Lovelace
Research Type: Journal Article

Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea.
2023
Youssef Bessada, V Ashton, B K Bookhart, Katelyn Galli, Craig Coleman, N Sood
Research Type: Journal Article

Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies.
2023
B K Bookhart, Craig Coleman, V Ashton, M S Roberts, K S Caroti, Youssef Bessada, William L Baker Jr.
Research Type: Journal Article

Response to the Letter by Spurling and Colleagues.
2023
S J Connolly, M J Christoph-Schubel, Craig Coleman, J Beyer-Westendorf, B Lovelace, M Sharma, O S Costa
Research Type: Other Scholarly Work

Effectiveness of High- Versus Low-Dose Four-Factor Prothrombin Complex Concentrate on Hemostasis and Thromboembolism in Patients with Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage
2023
Craig Coleman, William L Baker Jr.
Research Type: Poster/Presentation

High risk of bias in studies assessing reversal and replenishment replacement agents for factor Xa inhibitor bleeding.
2023
Craig Coleman, Charles M White, Paul Dobesh, Youssef Bessada, William L Baker Jr., Adrian V Hernandez Diaz, Kimberly Snow Caroti
Research Type: Poster/Presentation

COMPARATIVE EFFECTIVENESS AND SAFETY OUTCOMES OF REDUCED DOSE DOACS VS WARFARIN: A MULTINATIONAL COHORT STUDY OF INDIVIDUALS WITH AF
2023
Research Type: Poster/Presentation

PB1110 Implementation of International Society on Thrombosis and Haemostasis Definitions of Major and Clinically Relevant Non-Major Bleed Events in Electronic Health Records
2023
Research Type: Poster/Presentation